The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Daiichi Sankyo; Roche
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Roche; Seagan
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Roche
Expert Testimony - Exact Sciences
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
 
Thomas Karn
Patents, Royalties, Other Intellectual Property - Patent EP18209672 pending
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Merck; Molecular Health; MSD Oncology; Roche
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
 
Julia Rey
No Relationships to Disclose
 
Karsten Ernst Weber
No Relationships to Disclose
 
Uwe Holtrich
No Relationships to Disclose
 
Claus Hanusch
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Roche
 
Bruno Valentin Sinn
Patents, Royalties, Other Intellectual Property - Patent pending WO2017189976A1; Patent pending WO2020109570A1
 
Paul Jank
Stock and Other Ownership Interests - Myriad Genetics
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Hexal; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Hexal (Inst); Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Jens U. Blohmer
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Exact Sciences; Gilead Sciences; Lilly; Molecular Health; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Wolfgang D. Schmitt
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - Myriad Genetics
 
Marion van Mackelenbergh
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Genomic Health; Gilead Sciences; GlaxoSmithKline; Lilly; Molecular Health; Molecular Health; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Lilly
 
Christian Schem
No Relationships to Disclose
 
Elmar Stickeler
Honoraria - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Christian Jackisch
Honoraria - AstraZeneca; Exact Sciences; Lilly; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Molecular Health (Inst); MSD Oncology (Inst); Mylan (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Aurikamed; Bayer; Celgene; ClinSol; Connectmedica; Gilead Sciences; GlaxoSmithKline; I-MED; Lilly; MCI Deutschland; Metaplan; MSD; NanoString Technologies; Novartis; Onkowissen; Pfizer; Pierre Fabre; Promedicis; Roche; Seagen; Streamedup!; Tesaro; Teva; Thieme
Research Funding - Celgene (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Pfizer; Roche
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Medscape (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Samsung (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)